We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ready Source of Functional Liver Cells Should Boost Drug Development Efforts

By LabMedica International staff writers
Posted on 09 Aug 2015
Liver function in newborns kicks in only after exposure to certain nutrient factors derived from gut bacteria, and this phenomenon has been used to differentiate pluripotent stem cells into fully functional liver cells (hepatocytes). More...


Investigators at the Hebrew University of Jerusalem (Israel) found that fetal hepatocytes acquired mature CYP450 (cytochrome P450) expression only after birth, suggesting that nutritional cues were required to drive hepatic maturation. Subsequently, they showed that vitamin K2 and lithocholic acid, a by-product of intestinal flora, activated pregnane X receptor (PXR) and CYP3A4 and CYP2C9 expression in isolated fetal hepatocytes.

Human pluripotent stem cells (hPSCs) represent an excellent source of differentiated hepatocytes; however, current protocols still produce fetal-like hepatocytes with limited mature function. In the current study, the investigators induced hPSCs to differentiate into fully functional mature hepatocytes by augmenting their growth medium with vitamin K2 and lithocholic acid.

They reported in the July 2015 issue of the journal Hepatology that differentiated cells produced albumin and apolipoprotein B100 at levels equivalent to primary human hepatocytes. Flow cytometry showed that over 83% of cells were albumin and hepatocyte nuclear factor 4 alpha (HNF4α) positive, which permitted high-content screening in a 96-well plate format. Stem cell–derived hepatocytes demonstrated all toxicological endpoints examined, including steatosis, apoptosis, and cholestasis, when exposed to nine known hepatotoxins.

“This is quite a revolution for pharmaceutical drug discovery,” said senior author Dr. Yaakov Nahmias, professor of bioengineering at the Hebrew University of Jerusalem. “While other groups have been able to produce liver cells before us, their cells showed little functional activity, and could not be reliably used for drug discovery. In fact, up until now stem cell-derived hepatocytes showed little ability to predict clinical outcome. The limited availability of functional hepatocytes for drug testing is a major bottleneck bringing pharmaceutical companies to spend USD one billion [per] year on liver cells alone. Our ability to produce an unlimited supply of functional liver cells from human pluripotent stem cells can change all that.”

Related Links:

Hebrew University of Jerusalem



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.